Full text is available at the source.
Abstract
Clinical studies have identified specific gut microbiota and its metabolites associated with the efficacy of immunotherapy in multiple types of cancers.
- Gut microbiota may play a significant role in the development of malignant tumors.
- Preclinical investigations indicate that gut microbiota can influence antitumor immunity.
- Certain microbiota and their metabolites could remodel the tumor microenvironment by interacting with immune cells.
- Fecal microbial transplants, probiotics, and dietary interventions have shown promise in enhancing immunotherapy in preclinical studies.
- Ongoing clinical trials are assessing various strategies to target the microbiota for improved cancer treatment.
Simplified